Patents by Inventor Albert F. Lobuglio

Albert F. Lobuglio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING BREAST CANCER
    Publication number: 20190375806
    Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.
    Type: Application
    Filed: August 27, 2019
    Publication date: December 12, 2019
    Inventors: Katherine E VARLEY, Richard M MYERS, Brian S ROBERTS, Jason GERTZ, Donald J Buchsbaum, Andres Forero-Torres, Albert F LoBuglio
  • Treating basal-like genotype cancers
    Patent number: 10316100
    Abstract: Provided herein are methods of treating a subject with cancer comprising administering to the subject a death receptor agonist. Also provided herein are methods of screening a breast cancer cell for responsiveness to a DR5 agonist. Further provided herein are antibodies that selectively bind an N-terminal CARD of DDX3, a DDX3 lacking an N-terminal CARD, and an 80 kDa baculovirus TAP repeat (BIR).
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: June 11, 2019
    Assignee: The UAB Research Foundation
    Inventors: Donald J. Buchsbaum, Tong Zhou, Albert F. LoBuglio
  • Novel Read-Through Fusion Polynucleotides and Polypeptides and Uses Thereof
    Publication number: 20170267733
    Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 21, 2017
    Inventors: Katherine E. Varley, Richard M. Myers, Brian S. Roberts, Jason Gertz, Donald J. Buchsbaum, Andres Forero-Torres, Albert F. LoBuglio
  • Treating basal-like genotype cancers
    Patent number: 9527915
    Abstract: Provided herein are methods of treating a subject with cancer comprising administering to the subject a death receptor agonist. Also provided herein are methods of screening a breast cancer cell for responsiveness to a DR5 agonist. Further provided herein are antibodies that selectively bind an N-terminal CARD of DDX3, a DDX3 lacking an N-terminal CARD, and an 80 kDa baculovirus TAP repeat (BIR).
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: December 27, 2016
    Assignee: The UAB Research Foundation
    Inventors: Donald J. Buchsbaum, Tong Zhou, Albert F. LoBuglio
  • Treating Basal-Like Genotype Cancers
    Publication number: 20160317551
    Abstract: Provided herein are methods of treating a subject with cancer comprising administering to the subject a death receptor agonist. Also provided herein are methods of screening a breast cancer cell for responsiveness to a DR5 agonist. Further provided herein are antibodies that selectively bind an N-terminal CARD of DDX3, a DDX3 lacking an N-terminal CARD, and an 80 kDa baculovirus TAP repeat (BIR).
    Type: Application
    Filed: July 20, 2016
    Publication date: November 3, 2016
    Applicant: The UAB Research Foundation
    Inventors: Donald J. Buchsbaum, Tong Zhou, Albert F. LoBuglio
  • Novel Read-Through Fusion Polynucleotides and Polypeptides and Uses Thereof
    Publication number: 20140162296
    Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.
    Type: Application
    Filed: March 14, 2013
    Publication date: June 12, 2014
    Inventors: Katherine E. Varley, Richard M. Myers, Brian S. Roberts, Jason Gertz, Donald J. Buchsbaum, Andres Forero-Torres, Albert F. LoBuglio
  • Targeting cancer stem cells with DR5 agonists
    Patent number: 8703712
    Abstract: Provided is a method of determining the level of resistance or sensitivity of cancer stem cells to a death receptor agonist. The method includes detecting the level of IAP in one or more DR5/DDX3/IAP complexes in or from the cancer stem cells. Also provided is a method of killing cancer stem cells in a subject and a method of reducing the risk of cancer recurrence in a subject.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: April 22, 2014
    Assignee: The UAB Research Foundation
    Inventors: Donald J. Buchsbaum, Albert F. Lobuglio, Tong Zhou, Kimberly Foreman
  • TARGETING CANCER STEM CELLS
    Publication number: 20130004521
    Abstract: Provided is a method of determining the level of resistance or sensitivity of cancer stem cells to a death receptor agonist. The method includes detecting the level of IAP in one or more DR5/DDX3/IAP complexes in or from the cancer stem cells. Also provided is a method of killing cancer stem cells in a subject and a method of reducing the risk of cancer recurrence in a subject.
    Type: Application
    Filed: March 18, 2011
    Publication date: January 3, 2013
    Applicants: LOYOLA UNIVERSITY CHICAGO, THE UAB RESEARCH FOUNDATION
    Inventors: Donald J. Buchsbaum, Albert F. Lobuglio, Tong Zhou, Kimberly Foreman
  • Combinations of antibodies selective for DR5 and other therapeutic agents
    Patent number: 7981421
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: July 19, 2011
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum
  • Treating Basal-Like Genotype Cancers
    Publication number: 20110104143
    Abstract: Provided herein are methods of treating a subject with cancer comprising administering to the subject a death receptor agonist. Also provided herein are methods of screening a breast cancer cell for responsiveness to a DR5 agonist. Further provided herein are antibodies that selectively bind an N-terminal CARD of DDX3, a DDX3 lacking an N-terminal CARD, and an 80 kDa baculovirus TAP repeat (BIR).
    Type: Application
    Filed: November 5, 2010
    Publication date: May 5, 2011
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Donald J. Buchsbaum, Tong Zhou, Albert F. LoBuglio
  • COMBINATIONS OF ANTIBODIES SELECTIVE FOR DR5 AND OTHER THERAPEUTIC AGENTS
    Publication number: 20110002887
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: January 13, 2010
    Publication date: January 6, 2011
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Tong Zhou, Donald J. Buchsbaum, Kimihisa Ichikawa, Jun Ohsumi
  • Combinations of antibodies selective for DR5 and other therapeutic agents
    Patent number: 7704502
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: April 27, 2010
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum
  • ANTIBODY SELECTIVE FOR DR4 AND USES THEREOF
    Publication number: 20090208483
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: August 7, 2008
    Publication date: August 20, 2009
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Tong Zhou, Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Donald J. Buchsbaum
  • Combinations of Antibodies Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Other Therapeutic Agents
    Publication number: 20090022707
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: May 22, 2007
    Publication date: January 22, 2009
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Tong Zhou, Donald J. Buchsbaum, Kimihisa Ichikawa, Jun Oshumi
  • Antibody selective for DR4 and uses thereof
    Patent number: 7476383
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: January 13, 2009
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Robert P. Kimberly, William J. Koopman, Albert F. Lobuglio, Donald J. Buchsbaum
  • Combinations of DR5 antibodies and other therapeutic agents
    Patent number: 7279160
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: October 9, 2007
    Assignee: The UAB Research Foundation
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. Lobuglio, Donald J. Buchsbaum
  • Melanoma antigens and methods of use
    Publication number: 20040136999
    Abstract: The present invention provides for isolated DNA and protein corresponding to novel melanoma tumor-associated antigens, antibodies directed towards the novel antigens of the present invention as well as methods of using the antigens for inhibiting the growth of a melanoma tumor and methods of screening compounds that inhibit the novel antigens of the present invention.
    Type: Application
    Filed: January 9, 2004
    Publication date: July 15, 2004
    Applicant: UAB Research Foundation
    Inventors: Theresa Strong, Robert M. Conry, Albert F. LoBuglio
  • Melanoma antigens and methods of use
    Patent number: 6677444
    Abstract: The present invention provides for isolated DNA and protein corresponding to novel melanoma tumor-associated antigens, antibodies directed towards the novel antigens of the present invention as well as methods of using the antigens for inhibiting the growth of a melanoma tumor and methods of screening compounds that inhibit the novel antigens of the present invention.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: January 13, 2004
    Assignee: UAB Research Foundation
    Inventors: Theresa Strong, Robert M. Conry, Albert F. LoBuglio
  • Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
    Publication number: 20030198637
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: October 31, 2002
    Publication date: October 23, 2003
    Inventors: Tong Zhou, Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Donald J. Buchsbaum
  • Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
    Publication number: 20030133932
    Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
    Type: Application
    Filed: October 25, 2002
    Publication date: July 17, 2003
    Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum